New Product Puts RBCC on Leading Edge of Organ Regeneration Research

The 3D printing of functional human organs could be a reality within the next decade, and Rainbow Coral Corp. (OTCBB: RBCC) is helping to lead the bioprinting revolution now underway.

Extremely promising breakthroughs in recent years have generated global interest in 3D bioprinting. Last August, Chinese researchers announced that they’d printed a small working kidney that lasted four months. In the U.S., researchers at Cornell University bioprinted a bionic ear last year, and San Diego firm Organovo showed promising results in printing human liver tissues.

With techniques and technology advancing rapidly, RBCC has positioned itself on the front lines of 3D bioprinting research through its joint venture with Nano3D Biosciences (n3D). The companies have teamed up to market and develop the BiO Assay, the first commercially available 3D bioprinter designed specifically for rapid, high-volume drug screening.

The automated toxicity assay uses biocompatible magnetic nanoparticles to print cells into 3D structures much faster and more affordably than competing bioprinting tech currently on the market. The automated toxicity assay uses biocompatible magnetic nanoparticles to print cells into 3D structures much faster and more affordably than competing bioprinting tech currently on the market.

“By making this technology available to researchers around the globe, we hope to advance the science of human cell culturing toward an era of 3D printed organ replacement and regeneration,” said RBCC CEO Kimberly Palmer.

RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and develop new medical and research technology innovations to compete alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). In 2012, Rainbow Biosciences acquired an equity interest in n3D.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.